Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

The goal of this clinical trial is to learn the safety of tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell in treating advanced gastric cancer in adults. It will also learn if the combined treatment works to treat advanced gastric cancer. The main questions it aims to answer are: What medical problems do participants have when using the combined treatment? Does tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell eliminate or shrink the tumor, and can it prolong the patient's survival period?

NCT Number	NCT07298200
Lead Sponsor	Jia Wei Collaborators: NeoCura
Conditions	Advanced Gastric Cancer
Enrollment	18 participants
Start Date	2025-12-26
Primary Completion	2028-06 (estimated)
Study Completion	2029-11 (estimated)
Updated on ClinicalTrials.gov	2026-02-25